BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...
DPA International on MSN20h
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...
Business Insider16h
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...
Benzinga.com7d
Breaking Down BioNTech: 16 Analysts Share Their Views
16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...
Bloomberg L.P.9d
BioNTech Beats Expectations, Gives Update on Cancer Drugs
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...
Seeking Alpha26d
BioNTech and Moderna: A tale of two mRNA developers
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...
Nasdaq5d
What Analysts Are Saying About BioNTech Stock
Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...
Benzinga.com4d
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...
Hosted on MSN3mon
German pharma company BioNTech records multimillion euro loss
The German pharmaceutical company BioNTech reported a substantial loss in the second quarter as it continues to advance towards the approval of new products, including innovative cancer therapies.
pharmaphorum3y
BioNTech takes its first cancer vaccine into phase 2
It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.
FierceBiotech26d
BioNTech-OncoC4 phase 3 cancer trial under partial hold after varying results reported
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...